Poltreg S.A. (WSE:PTG)

Market Cap	79.28M -50.6%
Revenue (ttm)	n/a -75.0%
Net Income	-24.56M
EPS	-5.27
Shares Out	4.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,033
Average Volume	6,080
Open	17.50
Previous Close	17.45
Day's Range	17.00 - 17.50
52-Week Range	16.00 - 37.00
Beta	0.88
RSI	40.70
Earnings Date	Sep 9, 2026

About Poltreg

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 33
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PTG

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.